TILL TRANSAKTIONER
Hälsovård

InNeuroCo has been acquired by Integer

The owners of InNeuroCo has sold the company to Integer (NYSE:ITGR).

Founded in 2014 and headquartered in Pembroke Pines, Florida, InNeuroCo is a leading founder-owned designer and contract manufacturer of ultra-precise, highly engineered neurovascular catheters. InNeuroCo’s primary products are single-use catheters principally used in interventional neurovascular procedures for the treatment of ischemic strokes and aneurysms. Offering turnkey product design and development, supported by comprehensive domestic manufacturing capabilities, InNeuroCo serves as a mission-critical supply partner to the world’s preeminent medical device OEMs.

With approximately US$1.4 billion in annual revenue, Integer is one of the largest medical devices outsource manufacturers in the world, serving the cardiac, vascular, rhythm management and neuromodulation markets.

Oaklins TM Capital in the US served as the exclusive financial advisor to InNeuroCo in its sale to Integer (NYSE:ITGR).

Uppdrag
Företagsförsäljning
Parter
“InNeuroCo’s founders have enjoyed a long-standing history of success with the Oaklins TM healthcare team. When we began contemplating a transaction for InNeuroCo, it was the obvious choice to serve as our advisor. Throughout this transaction, their knowledge of the neurovascular sector, valuable strategic insights and demonstrated expertise in contract medical manufacturing were critical to engineering a successful outcome for InNeuroCo. We appreciate the team’s tireless dedication and thoughtful approach.”

Marc Litzenberg

President and CEO, InNeuroCo

Prata med transaktionsteamet

James McLaren

James McLaren

Managing Director
New York, USA
Oaklins TM Capital
Se profil Kontakta oss
John Dean

John Dean

Managing Director
Atlanta, USA
Oaklins TM Capital
Se profil Kontakta oss
Michael S. Goldman

Michael S. Goldman

Managing Director
New York, USA
Oaklins TM Capital
Se profil Kontakta oss
Bradley S. Goldstein

Bradley S. Goldstein

Associate Director
Atlanta, USA
Oaklins TM Capital
Se profil Kontakta oss
Matthew Halbig

Matthew Halbig

Analyst
Atlanta, USA
Oaklins TM Capital
Se profil Kontakta oss

Relaterade transaktioner

MEDIK Hospital Design Group has been acquired by STERIS
Bygg- & tekniktjänster | Hälsovård

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Lär dig mer
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Hälsovård

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Lär dig mer
SLT has been acquired by Indutrade
Hälsovård

SLT has been acquired by Indutrade

SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.

Lär dig mer